Yorktown Management & Research Company’s Amphastar Pharmaceuticals AMPH Stock Holding History

Yorktown Management & Research Company’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,600	Closed	-$245K	–	208
2024 Q4	$245K	Buy	+6,600	New	+$302K	0.24%	194
2024 Q1	–	Sell	-5,700	Closed	-$353K	–	220
2023 Q4	$353K	Hold	5,700	–	–	0.37%	127
2023 Q3	$262K	Buy	+5,700	New	+$311K	0.29%	185

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Yorktown Management & Research Company's AMPH Position: Q1 2025 in Review

Yorktown Management & Research Company sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 6,600 shares — an estimated $245K sold.

Yorktown Management & Research Company first reported a position in AMPH in Q3 2023 and held it in 3 quarters. The position peaked at $353K in Q4 2023. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

Yorktown Management & Research Company reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Yorktown Management & Research Company sold 6,600 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $245K.
Yorktown Management & Research Company first reported a position in Amphastar Pharmaceuticals in Q3 2023 and held it in 3 quarters.
Yorktown Management & Research Company's Amphastar Pharmaceuticals position peaked at $353K in Q4 2023.
241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Yorktown Management & Research Company's 13F filing for Q1 2025, filed 23 Apr 2025.